1 / 56

ISAC XX WORKSHOP Carleton C. Stewart Sigrid J. Stewart

RPCI. LFC. ISAC XX WORKSHOP Carleton C. Stewart Sigrid J. Stewart. RPCI. LFC. IMMUNOPHENOTYPING ACUTE LEUKEMIAS. Types of Antigen Expression. A. B. C. Ab2. Ab2. Ab2. Ab1. Ab1. Ab1. D. E. F. Ab2. Ab2. Ab2. Ab1. Ab1. Ab1. T-Lineage Acute Lymphocytic Leukemia. FITC-CD7.

neith
Download Presentation

ISAC XX WORKSHOP Carleton C. Stewart Sigrid J. Stewart

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. RPCI LFC ISAC XXWORKSHOPCarleton C. StewartSigrid J. Stewart

  2. RPCI LFC IMMUNOPHENOTYPING ACUTE LEUKEMIAS

  3. Types of Antigen Expression A B C Ab2 Ab2 Ab2 Ab1 Ab1 Ab1 D E F Ab2 Ab2 Ab2 Ab1 Ab1 Ab1

  4. T-Lineage Acute Lymphocytic Leukemia FITC-CD7 PE-CD4 FITC-CD3 FITC-CD3 TC-CD8 TC-CD2 FITC-CD45 PE-CD19 PE-CD34 FITC-CD5 FITC-CD5 PP-HLADr 08076102

  5. MARKER EXPRESSION ON T-CELL ALL n = 54 > 10% of leukemia cells express the marker

  6. MARKER EXPRESSION ON B-CELL ALL n =284

  7. PRE-B-CELLS BONE MARROW BLOOD CD19 CD19 CD10 CD10 RPCI LFC 02178081.004 11065003

  8. CD19 CD20 CD10 CD10 CD34 CD45 CD19 CD19

  9. FEATURES OF ERYTHROLEUKEMIA (FAB M6) SSC CD34 CD45 FSC CD45 SSC 12017021016

  10. Phenotype of Myeloid Component of Erythroleukemia 3/18 erythroleukemias did not exhibit a myeloid component 4/16 erythroleukemias exhibit a megakaryocytic component

  11. MARKER EXPRESSION ON AML CELLS n = 957 > 10% of leukemia cells express the marker 4% of specimens diagnosed by hematopathology as AML were found to have ALL or were normal by Flow Cytometry.

  12. RPCI LFC IMMUNOPHENOTYPING LYMPHOPROLIFERATIVE DISEASE multiple myeloma T-cell lymphomas

  13. MULTIPLE MYELOMA PE-CD56 PE-CD56 FITC-CD38 FITC-CD45 FITC-CD20 PC-CD19 FITC-CD5 TC-CD22 11296291

  14. 1 2 3 4 10 1 10 2 10 3 10 4 BONE MARROW FROM MULTIPLE MYELOMA PATIENT STAINED WITH CD38 CD56 AND CD45 PE-CD56 FITC-CD38

  15. BONE MARROW FROM MULTIPLE MYELOMA PATIENT STAINED FOR CD38 CD56 CD45 AND DNA CONTENT GATED ON MONONUCLEAR CELLS GATED ON CD38+CD56+CD45- CELLS 800 120 700 100 90 600 80 Number 500 70 60 400 50 300 40 30 200 20 100 10 10 30 50 70 90 110 140 170 200 230 10 30 50 70 90 110 140 170 200 230 DNA

  16. Typical T-cell Lymphoma or Reactive Lymph Node:

  17. NON MALIGNANT LYMPH NODE -T CELLS TC-CD8 PE-CD4 PE-CD4 FITC-CD3 TC-CD8 FITC-CD3 FITC-CD7 FITC-CD5 TC-CD2 TC-CD10

  18. SEZARY CELL LEUKEMIA TC-CD4 PE-CD3 PE-CD3 FITC-CD71 PE-CD25 FITC-CD45 FITC-CD3 PP-HLADr 11126101

  19. T-CELL Large Granular Lymphocytic Leukemia PE-CD4 FITC-CD3 TC-CD3 FITC-CD3 TC-CD8 FITC-CD57 FITC-CD45 PE-CD56 FITC-CD7 TC-CD3 TC-CD2 PP-HLADr 08226202

  20. IMMUNOPHENOTYPING LYMPHOPROLIFERATIVE DISEASE B-cell/CLL RPCI LFC

  21. NON-MALIGNANT LYMPH NODE-B CELLS PC-CD19 PC-CD19 FITC-CD20 FITC-CD5 TC-CD10 TC-CD22 PE-lambda PE-CD79 PE-IgM FITC-kappa FITC-IgD FITC-CD23 01148261

  22. Aberrant Antigen Coexpression in B-cell lymphoma

  23. A B C Lambda Lambda Kappa Kappa CD19 CD19 D E F CD13 CD13 CD33 CD33 CD19 CD19 Problem Case

  24. CHRONIC LYMPHOCYTIC LEUKEMIA PE-CD19 PE-CD19 FITC-CD20 FITC-CD5 TC-CD10 TC-CD22 GATED ON CD19 POSITIVE B-CELLS FOR CLARITY PE-IgM PE-CD79 PE-Lambda FITC-Kappa FITC-IgD FITC-CD23 01078121

More Related